The present invention relates to 1-(1-methylethyl)-4-{4-(tetrahydro-2H-pyran-4-yloxy)phenylcarbonyl} piperazine (Formula) or a pharmaceutically acceptable salt thereof in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases such as cognitive impairment fatigue or a sleep disorder f...

The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]car bonyl}piperazine (Formula) or a pharmaceutically acceptable salt thereof in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases such as cognitive impairment fatigue or a sleep disorder...

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity processes for their preparation to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

The present invention discloses a compound of the general formula (I): namely (2S)-2-amino-4-{[2-(ethanimidoylamino)ethyl]thio}butanoic acid compound with phosphoric acid or a solvate or physiologically functional derivative thereof is useful as a relatively non-hygroscopic selective inhibitor of inducible nitric oxide synthase. The above-indicated compounds are used in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of NO synthase ...

A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the CaV2.2 calcium channels is beneficial.

A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Polymorphic forms 1 and 2 of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2- methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid pharmaceutical compositions comprising such polymorphs and the use of such polymorphs in medicine.